He Sun

发表

On the recording of sample times and parameter estimation from repeated measures pharmacokinetic data

E. Ette, T. Ludden, He Sun, 1996, Journal of Pharmacokinetics and Biopharmaceutics.

Balanced Designs in Longitudinal Population Pharmacokinetic Studies

He Sun, E. Ette, T. Ludden, 1998, Journal of clinical pharmacology.

Absence of an effect of T89 on the steady‐state pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers

Ping Wang, He Sun, Zhi-xin Guo, 2014, Journal of clinical pharmacology.

Preclinical pharmacology of the natural product anticancer agent 10-hydroxycamptothecin, an inhibitor of topoisomerase I

Ruiwen Zhang, Tiepu Liu, Q. Cai, 1998, Cancer Chemotherapy and Pharmacology.

Population Pharmacokinetics

K. Higgins, Shiew-Mei Huang, L. Lesko, 1999 .

Leveraging Prior Quantitative Knowledge to Guide Drug Development Decisions and Regulatory Science Recommendations: Impact of FDA Pharmacometrics During 2004–2006

Yaning Wang, Lawrence J Lesko, Rajanikanth Madabushi, 2008, Journal of clinical pharmacology.

The Time to Reach Steady State After the Administration of Intravenous Bolus, Constant Infusion, and Oral Immediate‐Release and Sustained‐Release Preparations

M. Chow, He Sun, 1990, Pharmacotherapy.

The Process of Knowledge Discovery from Large Pharmacokinetic Data Sets

Ene I. Ette, Paul Williams, He Sun, 2001, Journal of clinical pharmacology.

FDA Guidance for Industry 1 Extended Release Solid Oral Dosage forms: Development, Evaluation, and Application of In Vitro/In Vivo Correlations

Vinod P. Shah, Ajaz S. Hussain, William R. Gillespie, 1997 .

Ignorability and Parameter Estimation in Longitudinal Pharmacokinetic Studies

E. Ette, T. Ludden, H. Sun, 1998, Journal of clinical pharmacology.

Designing Cross-Sectional Population Pharmacokinetic Studies: Implications for Pediatric and Animal Studies

E. Ette, C. D. Jones, He Sun, 1996 .

Adverse Drug Reactions: A Review of Relevant Factors

F. Ajayi, He Sun, J. Perry, 2000, Journal of clinical pharmacology.